Acipimox
- Generic Name
- Acipimox
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C6H6N2O3
- CAS Number
- 51037-30-0
- Unique Ingredient Identifier
- K9AY9IR2SD
- Background
Acipimox is a niacin derivative used as a hypolipidemic agent. It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid. Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a mode...
- Indication
Used in the treatment of hyperlipidemias (abnormally elevated levels of any or all lipids and/or lipoproteins in the blood).
- Associated Conditions
- Fredrickson classification type IV Hyperlipidemia, Fredrickson type IIb hyperlipidemia
- Associated Therapies
- -
Co-Feedback Action of Growth Hormone, PP and PYY on Ghrelin in Bulimia
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Charles University, Czech Republic
- Target Recruit Count
- 24
- Registration Number
- NCT03338387
The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion
- First Posted Date
- 2016-06-13
- Last Posted Date
- 2018-05-08
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 8
- Registration Number
- NCT02796950
- Locations
- 🇩🇰
University Hospital of Aarhus, Aarhus, Denmark
Lipolytic Effects of GH in Hypopituitary Patients in Vivo
- First Posted Date
- 2016-05-25
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 9
- Registration Number
- NCT02782208
- Locations
- 🇩🇰
University Hospital of Aarhus, Aarhus, Denmark
In Vivo Specificity of KUC 7483 CL Co-administered With Bisoprolol, Propranolol, and Acipimox in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT02256722
The Impact of Free Fatty Acid (FFA-) Suppression on Myocardial Lipids and Function in Patients With Type 2 Diabetes
- First Posted Date
- 2013-11-11
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 8
- Registration Number
- NCT01980524
- Locations
- 🇦🇹
Division of Endocrinology and Metabolism, Internal Medicine III, Medical University of Vienna, Vienna, Austria
Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes
- First Posted Date
- 2013-03-22
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 28
- Registration Number
- NCT01816165
- Locations
- 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States
Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes
- First Posted Date
- 2012-04-19
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 13
- Registration Number
- NCT01580813
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
Effects of Acipimox on Mitochondrial Function in Obesity
- Conditions
- Interventions
- First Posted Date
- 2011-12-08
- Last Posted Date
- 2016-03-01
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT01488409
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Effect of Pharmacological Anti-lipolysis on FFA and VLDL-TG Metabolism Before and During Exercise
- First Posted Date
- 2010-12-15
- Last Posted Date
- 2012-09-18
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 9
- Registration Number
- NCT01260376
- Locations
- 🇩🇰
University Hospital of Aarhus, Norrebrogade, Aarhus, Denmark
The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin
- Conditions
- Interventions
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2017-10-30
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 8
- Registration Number
- NCT01209416
- Locations
- 🇩🇰
University Hospital of Aarhus, Aarhus, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.